Skip to search formSkip to main contentSkip to account menu

Clozaril

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Objective Clozapine is the treatment of choice for refractory schizophrenia. The aim of this study was to compare the… 
2010
2010
To investigate the bioequivalence of the three clozapine brands licensed in the United Kingdom, we compared plasma clozapine and… 
2010
2010
This study prospectively assessed outcomes in a group of patients who were randomly switched from Clozaril to generic clozapine… 
Review
2007
Review
2007
ABSTRACT. The antipsychotic agent clozapine (Clozaril®) is reserved for the treatment of refractory psychosis. Clozapine has… 
2006
2006
Summary Two generic preparations of clozapine have been licensed in the UK. The bioequivalence of these products compared with… 
Review
2003
Review
2003
As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to… 
2001
2001
OBJECTIVE: To evaluate safety and dosage requirements when patients taking brand-name clozapine (Clozaril, Novartis… 
1999
1999
AbstractObjective: This inpatient, randomised, three-way crossover study evaluated the steady-state pharmacokinetics and… 
1995
1995
1. Clozaril, an atypical antipsychotic, did not gain approval for use in Australia until 1992. Prior to its general release, a… 
1992
1992
Clozaril, an antipsychotic agent, has several harmful side effects. An established computerized database was used to monitor…